DK2214656T3 - Sammensætninger og fremgangsmåder til at forstærke immunrespons - Google Patents

Sammensætninger og fremgangsmåder til at forstærke immunrespons Download PDF

Info

Publication number
DK2214656T3
DK2214656T3 DK08842588.9T DK08842588T DK2214656T3 DK 2214656 T3 DK2214656 T3 DK 2214656T3 DK 08842588 T DK08842588 T DK 08842588T DK 2214656 T3 DK2214656 T3 DK 2214656T3
Authority
DK
Denmark
Prior art keywords
polymeric material
antigen
infection
oxbc
cells
Prior art date
Application number
DK08842588.9T
Other languages
English (en)
Inventor
James Johnston
Graham Burton
Bozena Korczak
Original Assignee
Avivagen Inc
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avivagen Inc, Nat Res Council Canada filed Critical Avivagen Inc
Application granted granted Critical
Publication of DK2214656T3 publication Critical patent/DK2214656T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (14)

1. Polymermateriale og et antigen til anvendelse til behandling afen infektion, hvor polymermaterialet har en molekylevægt på mere end 1.000 Dalton og er opnåelig ved at reagere 6 til 8 molækvivalenter oxygen eller en ækvivalent mængde oxygen fra et andet oxidationsmiddel med et karotenoid.
2. Polymermateriale og et antigen til anvendelse til forebyggelse af en infektion, hvor polymermaterialet har en molekylevægt på mere end 1.000 Dalton og er opnåelig ved at reagere 6 til 8 molækvivalenter oxygen eller en ækvivalent mængde oxygen fra et andet oxidationsmiddel med et karotenoid.
3. Polymermateriale og antigen til anvendelse ifølge krav 1 eller 2, hvor polymermaterialet er formuleret til oral, intravenøs, okulær, intramuskulær, topikal, subkutan eller intranasal indgivelse.
4. Polymermateriale og antigen til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor infektionen er ved en bakterie, virus, svamp eller parasit; eller hvor infektionen er valgt fra gruppen bestående af lungebetændelse erhvervet uden for hospitalsmiljø (community-acquired pneumonia), infektion i de øvre og nedre luftveje, hud- og blødvævsinfektion, akut bakteriel mellemørebetændelse, bakteriel lungebetændelse, nyrebækkenbetændelse, intra-abdominal infektion, bakteriel sepsis, infektion i centralnervesystemet, bakteriæmi, sårinfektion, bughindebetændelse, meningitis, infektion efter forbrænding, urinvejsinfektion, underlivsbetændelse, endokarditis og intravaskulær infektion; eller hvor polymermaterialet er formuleret til indgivelse via øjet; eller hvor polymermaterialer er formuleret til indgivelse via munden hos et individ.
5. Polymermateriale og antigen til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor polymermaterialet og antigenet anvendes i kombination med et antibiotikum.
6. Polymermateriale til anvendelse til forstærkning af det adaptive immunrespons for et antigen hos et individ der immuniseres, hvor polymermaterialet har en molekylevægt på mere end 1.000 Dalton og er opnåelig ved at reagere 6 til 8 molækvivalenter oxygen eller en ækvivalent mængde oxygen fra et andet oxidationsmiddel med et karotenoid.
7. Polymermateriale til anvendelse ifølge krav 6, hvor polymermaterialet indgives oralt, intravenøst, okulært, intramuskulært, topikalt, subkutant eller intranasalt.
8. Polymermateriale til anvendelse ifølge krav 6, hvor antigenet er afledt fra et patogen, såsom en bakterie, virus, svamp eller parasit; eller hvor antigenet er et kulhydrat, glycolipid, glycoprotein, lipid, protein, lipoprotein, phospholipid eller polypeptid; eller hvor antigenet er afledt fra en levende eller en svækket levende virus; eller hvor antigenet er afledt fra et patogen valgt fra miltbrand, influenza, polio, mæslinger og rabies; eller hvor polymermaterialet indgives inden for 14 dage af antigenet; eller hvor polymermaterialet indgives samtidigt med antigenet.
9. Polymermateriale til anvendelse til forstærkning af immunrespons hos et individ der har, eller er i fare for, en infektion, hvor polymermaterialet har en molekylevægt på mere end 1.000 Dalton og er opnåelig ved at reagere 6 til 8 molækvivalenter af oxygen eller en ækvivalent mængde oxygen fra et andet oxidationsmiddel med et karotenoid.
10. Polymermateriale til anvendelse ifølge krav 9, hvor polymermaterialet indgives oralt, intravenøst, okulært, intramuskulært, topikalt, subkutant eller intranasalt.
11. Polymermateriale og antigen til anvendelse ifølge et hvilket som helst af kravene 1-5, eller polymermaterialet til anvendelse ifølge et hvilket som helst af kravene 6 til 10, hvor karotenoidet er valgt fra gruppen bestående af β-karoten, lycopen, lutein og canthaxanthin.
12. Polymermateriale og antigen til anvendelse ifølge krav 11 eller polymermaterialet til anvendelse ifølge krav 11, hvor karotenoidet er β-karoten.
13. Farmaceutisk sammensætning omfattende et polymermateriale og et antigen, hvor polymermaterialet har en molekylevægt på mere end 1.000 Dalton og er opnåelig ved at reagere 6 til 8 molækvivalenter af oxygen eller en ækvivalent mængde oxygen fra et andet oxidationsmiddel med et karotenoid.
14. Farmaceutisk sammensætning ifølge krav 13, hvor sammensætningen er formuleret til oral, intravenøs, intramuskulær, oftalmisk, topikal, subkutan eller intranasal indgivelse; eller hvor antigenet er afledt fra et patogen, såsom en bakterie, virus, svamp eller parasit; eller hvor antigenet er et kulhydrat, glycolipid, glycoprotein, lipid, protein, lipoprotein, phospholipid eller polypeptid; eller hvor antigenet er afledt fra en levende eller en svækket levende virus; eller hvor antigenet er afledt fra et patogen valgt fra miltbrand, influenza, polio, mæslinger og rabies.
DK08842588.9T 2007-10-26 2008-10-23 Sammensætninger og fremgangsmåder til at forstærke immunrespons DK2214656T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58307P 2007-10-26 2007-10-26
PCT/CA2008/001879 WO2009052629A1 (en) 2007-10-26 2008-10-23 Compositions and methods for enhancing immune response

Publications (1)

Publication Number Publication Date
DK2214656T3 true DK2214656T3 (da) 2019-03-25

Family

ID=40579010

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08842588.9T DK2214656T3 (da) 2007-10-26 2008-10-23 Sammensætninger og fremgangsmåder til at forstærke immunrespons

Country Status (12)

Country Link
US (1) US10449247B2 (da)
EP (1) EP2214656B1 (da)
JP (2) JP2011500733A (da)
KR (1) KR101762753B1 (da)
CN (1) CN101909611A (da)
AU (1) AU2008316225B2 (da)
CA (1) CA2704098C (da)
DK (1) DK2214656T3 (da)
ES (1) ES2716474T3 (da)
NZ (1) NZ585620A (da)
PL (1) PL2214656T3 (da)
WO (1) WO2009052629A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003773A (es) 2004-09-28 2009-01-19 Chemaphor Inc Composiciones y metodos para promover ganancia de peso y conversion de alimentacion.
DK2214656T3 (da) 2007-10-26 2019-03-25 Avivagen Inc Sammensætninger og fremgangsmåder til at forstærke immunrespons
US10456369B2 (en) 2009-04-30 2019-10-29 Avivagen Inc. Methods and compositions for improving the health of animals
CA2790330A1 (en) * 2010-02-19 2011-08-25 Chemaphor Inc. Methods and compositions for use in aquaculture
EP2793851B1 (en) * 2011-12-21 2016-04-27 Novartis AG Contact lenses containing carotenoid and method for making same
CN102585007B (zh) * 2012-02-27 2013-12-04 华中农业大学 用于检测β-胡萝卜素类色素的单克隆抗体及酶联免疫方法与试剂盒
EP2874624B8 (en) * 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
US20180139985A1 (en) 2015-04-28 2018-05-24 Avivagen Inc. Oxidized carotenoids and components thereof for preventing necrotic enteritis
AU2016308076A1 (en) * 2015-08-20 2018-02-01 I.B.R. Israeli Biotechnology Research Ltd. Carotenoid compositions having antiviral activities and uses thereof
US20190054135A1 (en) * 2016-02-25 2019-02-21 Avivagen Inc. Plant or microorganism-derived carotenoid-oxygen copolymer compositions, methods of identifying, quantifying and producing same and uses thereof
JP2019094262A (ja) * 2016-03-31 2019-06-20 国立大学法人東北大学 低分子化合物アジュバント及びこれを用いたワクチン
JPWO2019189088A1 (ja) * 2018-03-27 2021-03-25 国立大学法人 東京大学 アジュバントおよび該アジュバントを含むワクチン
WO2020175936A1 (ko) * 2019-02-28 2020-09-03 단디바이오사이언스 주식회사 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물
CN112274630A (zh) * 2019-07-24 2021-01-29 台湾海洋大学 一种提高甲壳类免疫能力及抗病能力的方法及该藻红蛋白的用途及其组合物
US20230079333A1 (en) * 2020-02-18 2023-03-16 Avivagen Inc. Supplemented animal feeds for mammals
US11754753B2 (en) * 2020-04-27 2023-09-12 Coopervision International Limited Antioxidant contact lens
KR102583001B1 (ko) * 2021-02-10 2023-09-27 서울대학교산학협력단 클로렐라(Chlorella sp.)추출물 및 이의 페오피틴화 분획물 또는 이로부터 수득한 폴피린계 또는 카로테논계 화합물을 유효성분으로 포함하는 신종코로나 바이러스 감염의 예방 또는 치료용 조성물
CN114344453A (zh) * 2022-01-18 2022-04-15 华南师范大学 一种罗非鱼cl-k1在制备预防和/或治疗罗非鱼病害的药物中的应用
CN116616371A (zh) * 2023-05-24 2023-08-22 西安海吉焦生物科技研究院有限公司 四萜烯烃衍生物及其制备方法和应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2988045A (en) 1959-12-28 1961-06-13 Stanton E Fisher Animal toy
CH420822A (de) 1960-10-17 1966-09-15 Hoffmann La Roche Wasserdispergierbare Carotinoidzubereitung
GB1021537A (en) 1963-03-07 1966-03-02 Teijin Ltd Method of producing viscose rayon staple and a spinning apparatus for use in the method
CH552388A (de) 1970-07-10 1974-08-15 Hoffmann La Roche Lichtschutzmittel.
US3998753A (en) 1974-08-13 1976-12-21 Hoffmann-La Roche Inc. Water dispersible carotenoid preparations and processes thereof
US4333922A (en) 1974-09-12 1982-06-08 Herschler R J Method for the treatment of water-living animals with health modifying agents
DE2505869C3 (de) 1975-02-12 1978-05-18 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
DE2635802C2 (de) 1976-08-09 1984-03-01 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
US4234575A (en) 1979-01-31 1980-11-18 Rohm And Haas Company Phosphonoureide and phosphonothioureide anthelmintics
DE3009031C2 (de) 1980-03-08 1983-04-21 B.A.T. Cigaretten-Fabriken Gmbh, 2000 Hamburg Verfahren zur Herstellung von Aromastoffen für Rauchprodukte
US4642318A (en) 1982-11-17 1987-02-10 Klaus Wolff Method for decreasing radiation load in PUVA therapy
DK155415C (da) 1984-08-30 1989-08-14 Carsten Jensen Lehn Fremgangsmaade til fremstilling af tygge- og bideben
US4889847A (en) 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
NL8802848A (nl) 1988-11-18 1990-06-18 Naarden International Nv Werkwijze voor het bereiden van aroma- en reukstoffen.
AU623978B2 (en) 1989-02-28 1992-05-28 Nisshin Flour Milling Co. Ltd. Stabilized fat-soluble vitamin compositions
NL8901317A (nl) 1989-05-25 1990-12-17 Naarden International Nv Werkwijze voor het bereiden van aroma- en reukstoffen op basis van een of meer carotenoiden als uitgangsmateriaal.
US5047231A (en) 1989-05-30 1991-09-10 Nabisco Brands, Inc. Raw hide containing an inorganic pyrophosphate
US5290605A (en) 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
EP0406940A3 (en) 1989-06-30 1992-03-11 Unilever Nv Edible fat-containing products containing ester derivatives of vitamin e
DK595489D0 (da) 1989-11-27 1989-11-27 Neurosearch As Hydroxycarbonylderivater og fremgangsmaade til fremstilling af samme
US5225604A (en) 1989-11-27 1993-07-06 Neurosearch A/S Hydroxycarbonyl derivatives and process for making the same
JPH06197703A (ja) 1991-05-23 1994-07-19 Ajinomoto Takara Corp:Kk 畜産動物用飼料添加剤
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
JP2927961B2 (ja) 1992-02-07 1999-07-28 エム． クリグマン，アルバート 炎症性皮膚病の治療方法
US5252604A (en) 1992-07-10 1993-10-12 Hoffmann-La Roche Inc. Compositions of retinoic acids and tocopherol for prevention of dermatitis
US5310554A (en) 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
US6251953B1 (en) * 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
US5358915A (en) 1993-02-12 1994-10-25 American Colloid Company Process for regenerating spent acid-activated bentonite clays and smectite catalysts
JPH06276956A (ja) 1993-03-22 1994-10-04 Mikio Yamauchi 栄養組成物
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
ES2147762T3 (es) 1993-06-24 2000-10-01 Hoffmann La Roche Pigmentacion con carotenoides.
US5759528A (en) 1994-02-18 1998-06-02 Institute For Advanced Skin Research, Inc. Topical composition for promoting transdermal absorption of therapeutic agents
SE9401738D0 (sv) 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
US6080393A (en) 1994-07-09 2000-06-27 Johnson & Johnson Consumer Products, Inc. Skin care composition comprising a retinoid
US5475006A (en) 1994-08-10 1995-12-12 National Research Council Of Canada Extensively oxidized derivatives of carotenoids, retinoids and related conjugated polyenes useful as non-toxic cell-differentiation inducers, anti-proliferative agents, and anti-tumor agents
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
SE503336C2 (sv) 1994-09-19 1996-05-28 Asta Carotene Ab Medel och sätt för att öka produktionen av/hos fjäderfän
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
EP0718284B1 (en) 1994-12-21 1999-08-18 F. Hoffmann-La Roche Ag Carotenoid ketones and esters
US5635237A (en) 1995-01-31 1997-06-03 Rawhide Select Method of manufacturing substantially pure rawhide pet products
EP0824348B1 (en) 1995-05-05 2002-09-11 BRAIMAN, Mark S. Treatment of psoriasis with 11-cis-retinoic acid
US5719195A (en) 1995-05-05 1998-02-17 4 Thought Technologies Treatment of psoriasis with 11-cis-retinoic acid
DK0848592T4 (da) 1995-09-05 2005-04-11 Tetra Gmbh Antistressmidler til vanddyr
EP0955366B1 (en) * 1995-12-12 2006-09-06 Takara Bio Inc. Antigenic protein originating in malassezia
US6423743B1 (en) 1996-04-02 2002-07-23 Mars Incorporated Cocoa extract compounds and methods for making and using the same
US5673653A (en) 1996-09-26 1997-10-07 Sherrill; Les R. Chew toys for domestic carnivorous animals and method for making same
US6093427A (en) 1997-09-03 2000-07-25 T.F.H.Publications, Inc. Vegetable-based dog chew
US6110521A (en) 1996-10-25 2000-08-29 T.F.H. Publications, Inc. Wheat and casein dog chew with modifiable texture
US5941197A (en) 1997-01-17 1999-08-24 T.F.H. Publications, Inc. Carrot-based dog chew
US5874093A (en) 1996-11-15 1999-02-23 Eliaz; Isaac Cosmetic composition containing molecular oxygen
DE19651681A1 (de) 1996-12-12 1998-06-18 Basf Ag Stabile, wäßrige Dispersionen und stabile, wasserdispergierbare Trockenpulver von Xanthopyllen, deren Herstellung und Verwendung
US6133323A (en) * 1997-04-09 2000-10-17 The Iams Company Process for enhancing immune response in animals using β-carotene as a dietary supplement
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
AU6691598A (en) 1997-04-18 1998-11-13 Immudyne, Inc. Gel delivery system for animal nutrition and health
US6008254A (en) 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
JP4052534B2 (ja) 1997-11-27 2008-02-27 コーア株式会社 魚介類用薬剤及び飼料
SE511237C2 (sv) 1997-12-16 1999-08-30 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
US6223693B1 (en) 1997-12-30 2001-05-01 Hartz Mountain Corporation Soft rawhide article and method
US6171632B1 (en) 1998-03-09 2001-01-09 Purina Mills, Inc. Animal feed gel
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6159516A (en) 1999-01-08 2000-12-12 Tfh Publication, Inc. Method of molding edible starch
US6277420B1 (en) 1999-01-11 2001-08-21 David B. Andersen Combination rawhide and formulated food pet chew
FR2791566B1 (fr) 1999-03-31 2001-05-11 Oreal Composition contenant un actif instable en milieu oxydant, et ses utilisations notamment cosmetiques
SE9903619D0 (sv) * 1999-10-07 1999-10-07 Astacarotene Ab Use and method of treatment
US6433025B1 (en) 2000-04-13 2002-08-13 Cyanotech Corporation Method for retarding and preventing sunburn by UV light
EP1186245B1 (en) 2000-09-11 2017-10-18 DSM IP Assets B.V. Carotenoid esters
DE10048868A1 (de) 2000-10-02 2002-04-11 Basf Ag Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
DE10064387A1 (de) 2000-12-21 2002-06-27 Basf Ag Verfahren zur Herstellung von Trockenpulvern eines oder mehrerer Sauerstoff-haltiger Carotinoide
CN1638650A (zh) 2001-03-09 2005-07-13 雀巢制品公司 改善与年龄有关的生理缺陷并延长寿命的组合物
GB2374514A (en) 2001-04-20 2002-10-23 Nakajima Suisan Bio & Techno C Fish feed
EP1253131A1 (en) 2001-04-24 2002-10-30 Aventis Animal Nutrition S.A. Process for the preparation of an xanthophyll
GB0119052D0 (en) 2001-08-03 2001-09-26 Mars Uk Ltd Foodstuff
EP1455768A1 (en) 2001-12-07 2004-09-15 Eden Research Plc Respiratory infection prevention and treatment with terpene-containing compositions
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US20060127505A1 (en) 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US7253297B2 (en) 2002-02-06 2007-08-07 Dsm Ip Assetts B.V. Astaxanthin esters
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US6840196B2 (en) 2002-03-13 2005-01-11 Aspen Pet Products, Inc. Rawhide pet chew
KR100564386B1 (ko) 2002-05-13 2006-03-27 주식회사 마이코플러스 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물
US7001889B2 (en) 2002-06-21 2006-02-21 Merial Limited Anthelmintic oral homogeneous veterinary pastes
US6821538B2 (en) 2002-07-09 2004-11-23 T.F.H. Publications, Inc. Blends of starch and aliphatic-aromatic based polyester resins
GB0218932D0 (en) 2002-08-14 2002-09-25 Zoolife Internat Ltd Composition for dietary enrichment
RU2211048C1 (ru) 2002-08-14 2003-08-27 Люблинский Станислав Людвигович Средство для профилактики йоддефицитных состояний организма
CA2493748A1 (en) 2002-08-14 2004-02-26 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of macular and retinal disease
ITBS20020078A1 (it) * 2002-09-02 2004-03-03 Paoli Ambrosi Gianfranco De Composizione a base di trietil citrato nel trattamento delle infezioni di origine batterica della cute.
US6886496B1 (en) 2002-09-12 2005-05-03 Van H. Brown Pet chew toy
US20050205086A1 (en) 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
GB0225503D0 (en) 2002-11-01 2002-12-11 Zoolife Internat Ltd Gel feed
BR0317621B1 (pt) 2003-01-10 2013-02-05 brinquedo de mastigar e artigo resistente À mastigaÇço para animais domÉsticos carnÍvoros.
US6886497B1 (en) 2003-12-09 2005-05-03 Frank Jay Hague Animal chews
JP5559453B2 (ja) 2004-02-10 2014-07-23 ネステク ソシエテ アノニム カロテノイド化合物のシス異性体を含む組成物及び方法
EP1727530A4 (en) * 2004-02-19 2009-10-21 Chemaphor Inc TOPICAL FORMULATIONS FOR THE TREATMENT OF SKIN DISEASES
EP1755406B1 (en) 2004-04-16 2012-09-26 Nestec S.A. Compositions for reducing oxidative stress in an animal
MX2007003773A (es) 2004-09-28 2009-01-19 Chemaphor Inc Composiciones y metodos para promover ganancia de peso y conversion de alimentacion.
WO2006034556A1 (en) 2004-09-29 2006-04-06 Michael Ary Bos Caratenoid composition and method for preparation thereof
WO2006120494A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol
WO2006120496A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
DK1909594T3 (da) 2005-07-14 2015-05-26 Pmi Nutrition International Llc Gelbaseret husdyrfoder, fremgangsmåde til fremstilling og anvendelse
RU2008115148A (ru) * 2005-10-11 2009-11-20 Ликоред Лтд. (Il) Продукты окисления каротиноидов как химиопредупреждающие и химиотерапевтические агенты
US20090306222A1 (en) 2006-04-05 2009-12-10 Chemaphor Inc. Food supplements and uses thereof
US7985221B2 (en) * 2006-04-20 2011-07-26 Millennium Medical Technologies, Inc. External fixator
US20070282010A1 (en) 2006-05-30 2007-12-06 Bridge Pharma, Inc. Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
US20070298077A1 (en) 2006-06-21 2007-12-27 Jones Bradley E Consumable veterinary medicine delivery device
WO2008027235A1 (en) 2006-08-25 2008-03-06 University Of New Mexico Methods and compositions for control of disease in aquaculture
US20080107768A1 (en) 2006-09-29 2008-05-08 Industrial Organica, S.A. De C.V. Method for increasing the health condition of crustaceans in aquaculture
DK2214656T3 (da) 2007-10-26 2019-03-25 Avivagen Inc Sammensætninger og fremgangsmåder til at forstærke immunrespons
US10456369B2 (en) 2009-04-30 2019-10-29 Avivagen Inc. Methods and compositions for improving the health of animals
WO2010124392A1 (en) 2009-04-30 2010-11-04 Chemaphor Inc. Methods, compositions, and kits for the treatment of inflammatory conditions
CA2790330A1 (en) 2010-02-19 2011-08-25 Chemaphor Inc. Methods and compositions for use in aquaculture
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites

Also Published As

Publication number Publication date
EP2214656A1 (en) 2010-08-11
ES2716474T3 (es) 2019-06-12
KR20100102594A (ko) 2010-09-24
NZ585620A (en) 2013-03-28
CA2704098C (en) 2018-01-02
JP2011500733A (ja) 2011-01-06
CN101909611A (zh) 2010-12-08
JP6262158B2 (ja) 2018-01-17
JP2015110596A (ja) 2015-06-18
WO2009052629A1 (en) 2009-04-30
EP2214656B1 (en) 2018-12-05
AU2008316225A1 (en) 2009-04-30
EP2214656A4 (en) 2012-08-01
PL2214656T3 (pl) 2019-06-28
KR101762753B1 (ko) 2017-08-04
US20110217244A1 (en) 2011-09-08
AU2008316225B2 (en) 2014-06-19
US10449247B2 (en) 2019-10-22
CA2704098A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EP2214656B1 (en) Compositions and methods for enhancing immune response
US11419904B2 (en) Immunomodulatory compositions and methods of use thereof
US10946082B2 (en) Immunomodulatory compositions and methods of use thereof
TW200911274A (en) Alpha-galatosyl ceramide analogs and their use as immunotherapies
RU2010138410A (ru) Производные ретиналя и способы их применения для лечения нарушений зрения
US20230174581A1 (en) Processes and agents for glaucoma
WO2009006141A2 (en) Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
JP5569944B2 (ja) 抗感染薬およびその使用
HK1151481A (en) Compositions and methods for enhancing immune response
TWI293562B (en) Enhancers for enhancing the antibiotic activities of antibiotics and uses thereof in combination with antibiotics
TWI621435B (zh) 美諾四環素之醫藥組合物及其製備方法
US20140105970A1 (en) Adjuvant and antigen particle formulation
CA2996383C (en) Immunomodulatory compositions and methods of use thereof
WO2024173723A2 (en) Use of crassocephalum rabens extract in inducing humoral immune response
WO2025054577A1 (en) Nanoparticle based subunit vaccine for african swine fever virus
HK40102659A (zh) 病毒疫苗
MXPA06015161A (es) Composiciones adyuvantes y base de porinas de salmonella enterica serovar typhi.
US20120034252A1 (en) Compositions and methods for inducing an immune response
JP2019094262A (ja) 低分子化合物アジュバント及びこれを用いたワクチン
Kumar VETERINARY IMMUNOLOGY
JPWO2018074327A1 (ja) 粘膜免疫調節剤
HK1227730B (en) Immunomodulatory compositions and methods of use thereof